drugset / Trial / NCT01008007

Viusid in Adults With Acute Fever of Viral Etiology

NCT01008007

Phase 2 Completed 200 enrolled Catalysis SL
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of the study is to assess the safety and effect of Viusid (bags of 4 grams) administration in the treatment of acute fever of viral etiology as diagnosed by clinical, hematologic and serologic parameters. The duration of this open and randomized phase 2 clinical trial will be 6 days. The estimated number of persons with acute fever of viral etiology to be recruited and randomized for the study is 200. The primary outcome measure: platelet, leukocyte and granulocyte count will be assessed at the beginning and the end of the study.

Timeline

Start
2009-09
Primary completion
2010-05
Completion
2010-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Viusid Unknown 4 g Oral
Comparator Dimenhydrinate Small molecule 50 mg Intramuscular
Comparator dipyrone Unknown 600 mg Intramuscular

Indications

No indication recorded.